arrow
S

Stefano Severi

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori
H指数:28
被引数:2,403

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study

177Lu-PSMA-617放射性配体疗法的疗效、毒性和临床结局:一项前瞻性、单臂、II期研究,研究对象为每周期接受5.5 GBq剂量的晚期去势抵抗性前列腺癌患者

2025-11-270
OAAI
HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors
2023-01-203
OAAI
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma

嗅神经母细胞瘤中生长抑素受体2的临床结果,kdish-insica分期和治疗靶点

2022-02-0136
OAAI
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial
2021-07-3117
OAAI
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors
2021-02-1844
OAAI
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)

mCRPC (转移性去势抵抗性前列腺癌) 患者的靶向 α 治疗: 225Ac-PSMA (前列腺特异性膜抗原) 的预测剂量学和毒性模型

2020-11-0523
OAAI
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients
2020-05-2047
PREAI